Inclusion Criteria:

- Histologically confirmed diagnosis of advanced solid tumours or lymphoma, except for
primitive hepatocarcinoma for which radiological diagnosis only is permitted;

- Advanced or metastatic disease refractory to standard curative or palliative therapy
or contraindication or have refused standard therapy,

- Measurable and/or evaluable disease,

- Age ≥ 18 years,

- ECOG performance ≤ 1

- Life expectancy ≥ 3 months,

- If female, neither pregnant or lactating,

- Negative pregnancy test for females at screening, preferably done within 1 week
before Day 1 of treatment (not applicable to patients with bilateral oophorectomy
and/or hysterectomy),

- Agreeing to use appropriate medically approved contraception (physical barrier
contraception is recommended) from study entry to 6 months after the last day of
treatment for the patient,

- Absolute neutrophil count ≥ 1,500/µL; platelets ≥ 100,000/µL; calculated creatinine
clearance ≥ 60mL/min (calculated according to the formula of Cockroft and Gault);
total bilirubin ≤ 1.5x ULN; AST/ALT ≤ 2.5x ULN. In patients with documented liver
metastases, the AST/ALT may be ≤ 3.5x ULN; prothrombin time ≤1.5x ULN, kalemia,
magnesemia and phosphatemia > LLN (Lower Limit of Normal)

- Able to render informed consent and to follow protocol requirements,

- Able to swallow capsules,

- Able to comply with scheduled plans, laboratory tests, and other study procedures.

Exclusion Criteria:

- Received investigational agents or systemic anti-cancer agents within 14 days of Day
1 of treatment, or 28 days for those agents with unknown elimination half-lives, or
known elimination half-lives greater than 50 hours; or 6 weeks for Mitomycine C or
for nitrosourea agents,

- Unresolved toxicity from previous treatment or previous investigational agents,

- Patients with history of prior radiation that potentially included the heart in the
field (e.g. mantle),

- Cardiac exclusion criteria:

- History of significant coronary artery disease or congestive heart failure that
meets NYHA class III or IV, within 12 months (see Appendix D),

- Significant cardiovascular dysfunction : pulmonary hypertension, right
ventricular systolic dysfunction, aortic stenosis, mitral insufficiency > grade
2 and/or Left Ventricular Ejection fraction < 45% or < 55% if prior exposure to
anthracyclines, based on MUGA or echocardiography,

- Uncontrolled hypertension (Systolic > 150 or diastolic >100),

- Permanent and uncontrolled cardiac rhythm disorders and clinical relevant
abnormalities in 12-lead ECG/Holter, such as WPW (Wolff-Parkinson-White)
syndrome, QRS > 120 msec, PR > 220 msec, heart rate < 50 bpm, Q wave, ST
deviation, left bundle branch block, atrial fibrillation, flutter, tachysystoly.

- Prolonged QTc interval > 450 msec in men and > 470 msec in women using
Fridericia formula,

- Congenital long QT syndrome,

- Use of any medication associated with known QTc interval prolongation (a
non-exhaustive list will be provided separately)

- Known infection with human immunodeficiency virus (HIV), hepatitis B or hepatitis C,

- Patients with uncontrolled brain metastases,

- Gastrointestinal diseases or disorders that could affect drug absorption such as
diarrhoea, major abdominal surgery, significant bowel obstruction and/or
gastrointestinal diseases that could alter the assessment of safety, including any of
the following:

- Irritable bowel syndrome

- Ulcerative colitis

- Crohn disease

- Haemorrhagic coloproctitis

- Concurrent participation with any other anticancer therapy.